PCCA applauds the FDA for their decision and statement about Oxitriptan, which ensures that patients with BH4 deficiency can continue to receive the compounded medications they need.

Want some clarity on USP <797> and USP <800> updates? Our August updates to PCCA Play are designed to do just that with a free presentation from PCCA Education and Training Manager Jerra Banwarth, RPh, FIACP and Eagle President Ross Caputo, PhD. In another video, subscribers to PCCA Play can watch Eagle Vice President of Operations Megan Jeffrey Liotta, MS, discuss USP <797> regulation updates.

If you want to help your pharmacy stand out in a competitive field, it’s not enough to just say that you have quality products. Here are five ways that you can translate your investment in quality into your competitive advantage.

Congratulations to Stephen Anderson, RPh, of The Apothecary, Sartell, Minnesota for being our August Profile in Personalized Medicine. These profiles celebrate members of the PCCA family who have proven to be champions of Pharmacy Compounding by providing the highest quality of service to their patients.

Compounders who use progesterone in their formulations are faced with the question, "Should I used micronized or wettable progesterone?" With the help of PCCA's Clinical Services team, we're here to help guide you through making the best decision in specific situations.